Joseph W Kim, John Z Luo and Luguang Luo
Diabetes mellitus is a disease that poses a burden to the health care system due to its prevalence and chronic nature. Understanding β cell pathophysiology may lead to future therapeutic options for diabetes mellitus type 1 and 2. MicroRNAs (MiR) fine-tune β cell biochemical cascades through specific protein targets. This review argues that miRs may play a critical role in human islet β cell biology and are potential candidates for a new pharmacological strategy. We have reviewed and presented how miRs fine tune four biochemical cascades in islet β cells: glucose stimulated insulin secretion, β cell replication, apoptosis, and development. Only studies that examine human pancreatic islets either in vitro or in vivo are included. The unveiling role of miR pathways in regulating human islet β cell biology could open the door for diagnostic and therapeutic methods for diabetes mellitus prevention and therapy.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 